{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05006404",
            "orgStudyIdInfo": {
                "id": "AUT-CP-001"
            },
            "organization": {
                "fullName": "Autus Valve Technologies, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Autus Valve Pivotal Study",
            "officialTitle": "Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Pivotal Study",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "autus-valve-pivotal-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-02-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2036-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-23",
            "studyFirstSubmitQcDate": "2021-08-12",
            "studyFirstPostDateStruct": {
                "date": "2021-08-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Autus Valve Technologies, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.\n\nThe Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure."
        },
        "conditionsModule": {
            "conditions": [
                "Congenital Heart Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Autus Valve Arm",
                    "type": "EXPERIMENTAL",
                    "description": "Pulmonary Valve Replacement Surgery with the Autus Valve",
                    "interventionNames": [
                        "Device: Pulmonary Valve Replacement Surgery"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Pulmonary Valve Replacement Surgery",
                    "description": "Pulmonary valve replacement surgery with the Autus Valve",
                    "armGroupLabels": [
                        "Autus Valve Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Valve Implantation Primary Safety Endpoint",
                    "description": "Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:\n\n* Death;\n* Valve thrombosis requiring intervention;\n* Symptomatic thromboembolism.",
                    "timeFrame": "30 Days post-valve implantation"
                },
                {
                    "measure": "Valve Implantation Primary Effectiveness Endpoint",
                    "description": "Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:\n\n* A mean RVOT gradient less than or equal to 40 mmHg and\n* Less than moderate pulmonary regurgitation by transthoracic echo and\n* No Autus Valve reintervention except for valve expansion to address prosthesis-patient mismatch.",
                    "timeFrame": "6 Months post-valve implantation"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Other Safety Outcome - Composite",
                    "description": "The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:\n\n* Death;\n* Valve thrombosis requiring intervention;\n* Symptomatic thromboembolism.",
                    "timeFrame": "6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Mortality",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Mortality, including: all cause, cardiac-related, procedure-related and device-related",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Valve Thrombosis",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Valve thrombosis",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Thromboembolism",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Thromboembolism",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Cardiac or Valve Intervention",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Other cardiac or valve intervention (surgical or transcatheter)",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Major Hemorrhage",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Major hemorrhage",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Endocarditis",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Endocarditis",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Hemolysis",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Hemolysis",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Device Explantation",
                    "description": "The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Device explantation",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Adverse Events (AE)",
                    "description": "The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.\n\n\u2022 Adverse events",
                    "timeFrame": "30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation"
                },
                {
                    "measure": "Other Safety Outcome - Valve/Stent Fracture",
                    "description": "An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure.",
                    "timeFrame": "pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion."
                },
                {
                    "measure": "Other Effectiveness Outcome - Valve Implant Acute Procedural Success",
                    "description": "To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):\n\n* RV to PA peak systolic pressure gradient \\<40 mmHg (direct pressure measurement);\n* None or trivial pulmonary regurgitation (assessed via TEE);\n* No paravalvular leak (assessed via TEE).",
                    "timeFrame": "Immediately Post-Valve Implant Procedure"
                },
                {
                    "measure": "Other Effectiveness Outcome - Pulmonary Regurgitation Grade",
                    "description": "Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory.",
                    "timeFrame": "Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion."
                },
                {
                    "measure": "Other Effectiveness Outcome - Pulmonary Stenosis Grade",
                    "description": "Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory.",
                    "timeFrame": "Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion."
                },
                {
                    "measure": "Other Effectiveness Outcome - Right Ventricular Measures",
                    "description": "Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory.",
                    "timeFrame": "Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion."
                },
                {
                    "measure": "Other Effectiveness Outcome - Left Ventricular Measures",
                    "description": "Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory.",
                    "timeFrame": "Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion."
                },
                {
                    "measure": "Other Effectiveness Outcome - Modified Ross Functional Classification",
                    "description": "Modified Ross Functional Class as assessed by the Site Investigators",
                    "timeFrame": "Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion."
                },
                {
                    "measure": "Other Effectiveness Outcome - PedsQL - Cardiac Module",
                    "description": "The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel.",
                    "timeFrame": "Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion."
                },
                {
                    "measure": "Other Post-Implant Valve Expansion Safety Outcome - Composite",
                    "description": "Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:\n\n* Death;\n* Extracorporeal membrane oxygenation (ECMO) support;\n* Unplanned intervention (surgical or transcatheter);\n* Major hemorrhage",
                    "timeFrame": "30 days after each post-implant valve expansion procedure"
                },
                {
                    "measure": "Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success",
                    "description": "To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:\n\n* RV to aortic systolic pressure ratio: \u22640.5.\n* Peak-to-peak RV to PA systolic pressure gradient: \u226415 mmHg;\n* Peak-to-peak RV to PA systolic pressure gradient: \u226550% reduction (pre vs post valve expansion).",
                    "timeFrame": "Immediately after each post-implant valve expansion procedure"
                },
                {
                    "measure": "Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance",
                    "description": "Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:\n\n* Less than moderate pulmonary regurgitation (PR) by Doppler echocardiography;\n* Transvalvular gradient (assessed by CW Doppler) at 6-months is lower than the pre-expansion gradient.",
                    "timeFrame": "6 months after each post-implant valve expansion procedure"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nCandidates must meet all of the following inclusion criteria to be considered for enrollment in this study.\n\n1. Age 18 months to 16 years.\n2. Male or female.\n3. Subject has a native or repaired right ventricular outflow tract.\n4. Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).\n5. Subject has at least one of the following echocardiographic findings:\n\n   1. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient \u226560 mmHg);\n   2. Moderate or greater pulmonary regurgitation;\n   3. Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.\n6. Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).\n7. Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.\n8. Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if any of the following conditions are met:\n\n1. Subject requires valve replacement in a non-pulmonary position.\n2. Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).\n3. Subject has pulmonary arterial hypertension (defined as mean PA pressure \u226525 mmHg).\n4. Subject has pulmonary atresia and major aortopulmonary collaterals.\n5. Subject has significant peripheral pulmonary artery stenosis.\n6. Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).\n7. Subject has active endocarditis or a history of infective endocarditis.\n8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level \u22652.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.\n9. Subject has leukopenia (defined as a white blood cell (WBC) count \\<3.5 x 103/\u00b5L)\n10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) \\<10.0 g/dl or 6 mmol/L).\n11. Subject has thrombocytopenia (defined as platelet count \\<50 x 103/\u00b5L.\n12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.\n13. Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.\n14. Subject needs emergency cardiac or vascular surgery or intervention.\n15. Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.\n16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.\n17. Subject or parent/legal representative refuses blood transfusions.\n18. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.\n19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Months",
            "maximumAge": "16 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sophie-Charlotte Hofferberth, MD.",
                    "role": "CONTACT",
                    "phone": "617-390-6468",
                    "email": "shofferberth@autusvalve.com"
                },
                {
                    "name": "Paul Mehoudar, M.S.",
                    "role": "CONTACT",
                    "phone": "510-409-2255",
                    "email": "pmehoudar@yahoo.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sophie-Charlotte Hofferberth, MD",
                    "affiliation": "Autus Valve Technologies, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital Los Angeles",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90027",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "phone": "612-351-7835",
                            "email": "rbautista@chla.usc.edu"
                        },
                        {
                            "name": "Luke Wiggins, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Darren Berman, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Children's Hospital Colorado",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "email": "megyn.gordon@childrenscolorado.org"
                        },
                        {
                            "name": "James Jaggers, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Gareth Morgan, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Ann and Robert H. Lurie Children's Hospital of Chicago",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "email": "jbhavsar@luriechildrens.org"
                        },
                        {
                            "name": "Alan Nugent, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "David S Winlaw, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Boston Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "phone": "617-355-3515",
                            "email": "mariana.chavez@childrens.harvard.edu"
                        },
                        {
                            "name": "Christopher Baird, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Diego Porras, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Nicola Maschietto, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "University of Michigan - Mott Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "email": "ccislo@med.umich.edu"
                        },
                        {
                            "name": "Jennifer Romano, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Jeffrey Zampi, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "phone": "212-342-1562",
                            "email": "nk3136@cumc.columbia.edu"
                        },
                        {
                            "name": "Oliver Barry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Emile Bacha, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke University",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27703",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "email": "susan.hajmohammad@duke.edu"
                        },
                        {
                            "name": "Joseph Turek, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Gregory Fleming, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Nationwide Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43205",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "phone": "614-355-5763",
                            "email": "jolynne.carl@nationwidechildrens.org"
                        },
                        {
                            "name": "Mark Galantowicz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Aimee Armstrong, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "email": "bontragerc@chop.edu"
                        },
                        {
                            "name": "Stephanie Fuller, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Matthew Gillespie, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Seattle Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Coordinator",
                            "role": "CONTACT",
                            "email": "Jeremy.gillis@seattlechildrens.org"
                        },
                        {
                            "name": "Brian Morray, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Christina Greene, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000006330",
                    "term": "Heart Defects, Congenital"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000018376",
                    "term": "Cardiovascular Abnormalities"
                },
                {
                    "id": "D000000013",
                    "term": "Congenital Abnormalities"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "asFound": "Heart Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9418",
                    "name": "Heart Defects, Congenital",
                    "asFound": "Congenital Heart Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12",
                    "name": "Congenital Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M20503",
                    "name": "Cardiovascular Abnormalities",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                }
            ]
        }
    },
    "hasResults": false
}